Literature DB >> 10483511

Studies on the sedative and hypnotic effects of oleamide in mice.

J Y Yang1, C F Wu, H R Song.   

Abstract

The hypnotic and sedative effects of oleamide (CAS 301-02-0) were studied in mice. Intraperitoneal injection of oleamide showed a time-related inhibition of the locomotor activity with the maximum effect appearing 30 min after drug administration. Oleamide, at the dose range of 43.7-700 mg/kg, dose-dependently inhibited the locomotor activity in mice. Oleamide could promote the hypnotic action induced by sodium pentobarbital. The interaction studies showed that oleamide potentiated the inhibitory effect of diazepam (CAS 439-14-5) and antagonized the stimulatory effect of ethanol, methamphetamine, and caffeine, respectively. These results provide further evidence for the hypnotic and sedative effects of oleamide, suggesting a potential therapeutic usefulness of this fatty acid amide.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483511     DOI: 10.1055/s-0031-1300479

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Isolation of a sleep-promoting compound from Polygonatum sibiricum rhizome.

Authors:  Kyungae Jo; Hoon Kim; Hyeon-Son Choi; Seung-Su Lee; Myun-Ho Bang; Hyung Joo Suh
Journal:  Food Sci Biotechnol       Date:  2018-07-13       Impact factor: 2.391

2.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.

Authors:  James D Leggett; S Aspley; S R G Beckett; A M D'Antona; D A Kendall; D A Kendall
Journal:  Br J Pharmacol       Date:  2004-01-05       Impact factor: 8.739

3.  The serotonergic system may be involved in the sleep-inducing action of oleamide in rats.

Authors:  Jing-Yu Yang; Chun-Fu Wu; Fang Wang; Hong-Rui Song; Wen-Jun Pan; Yu-Ling Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-13       Impact factor: 3.000

Review 4.  Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

Authors:  Maureen L Petrunich-Rutherford; Michael W Calik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.